云南白药
(000538)
| 流通市值：1012.39亿 | | | 总市值：1018.99亿 |
| 流通股本：17.73亿 | | | 总股本：17.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,841,237,721.29 | 40,033,300,814.72 | 29,915,155,069.84 | 20,455,286,287.52 |
| 营业收入 | 10,841,237,721.29 | 40,033,300,814.72 | 29,915,155,069.84 | 20,455,286,287.52 |
| 二、营业总成本 | 8,751,171,876.26 | 35,206,797,286.5 | 25,480,753,830.78 | 17,225,017,022.4 |
| 营业成本 | 7,420,335,309.2 | 28,864,766,205.1 | 21,418,846,898.48 | 14,462,809,950.85 |
| 税金及附加 | 53,385,295.89 | 243,117,369.44 | 168,054,488.16 | 119,551,819.49 |
| 销售费用 | 1,070,132,434.21 | 4,879,502,036.91 | 3,306,476,038.21 | 2,296,821,490.59 |
| 管理费用 | 156,401,058.22 | 1,037,553,483.87 | 499,576,143.13 | 327,410,020.48 |
| 研发费用 | 60,122,221.9 | 337,413,301.03 | 216,182,636.47 | 148,043,019.34 |
| 财务费用 | -9,204,443.16 | -155,555,109.85 | -128,382,373.67 | -129,619,278.35 |
| 其中:利息费用 | 6,186,412.99 | 63,177,001.07 | 43,590,724.86 | 27,648,907.91 |
| 其中:利息收入 | 20,207,465.3 | 221,210,259.84 | 188,534,092.24 | 162,711,635.16 |
| 加:公允价值变动收益 | 40,964,635.95 | 136,837,009.94 | -18,774,131.35 | 4,596,876.81 |
| 加:投资收益 | 222,556,306.38 | 776,937,495.06 | 685,143,202.78 | 477,498,314.49 |
| 资产处置收益 | 81,785.84 | 490,651.65 | -1,484,474.56 | -1,592,134.63 |
| 资产减值损失(新) | -23,107,745.76 | -91,230,709.62 | -14,007,824.42 | -3,578,594.53 |
| 信用减值损失(新) | -90,587,139.08 | -39,925,926.62 | -130,560,162.1 | -82,762,335.12 |
| 其他收益 | 15,331,762.07 | 102,009,773.65 | 56,171,205.6 | 47,920,871.74 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,255,305,450.43 | 5,711,621,822.28 | 5,010,889,055.01 | 3,672,352,263.88 |
| 加:营业外收入 | 5,038,390.96 | 15,483,338.73 | 11,699,322.27 | 4,431,701.71 |
| 减:营业外支出 | 4,362,446.39 | 42,385,497.02 | 9,337,106.67 | 4,755,624.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,255,981,395 | 5,684,719,663.99 | 5,013,251,270.61 | 3,672,028,340.83 |
| 减:所得税费用 | 328,470,191.51 | 917,647,303.71 | 683,550,780.58 | 482,065,489.87 |
| 六、净利润 | 1,927,511,203.49 | 4,767,072,360.28 | 4,329,700,490.03 | 3,189,962,850.96 |
| 持续经营净利润 | 1,927,511,203.49 | 4,767,072,360.28 | 4,329,700,490.03 | 3,189,962,850.96 |
| 归属于母公司股东的净利润 | 1,934,639,584.6 | 4,749,415,499.55 | 4,326,728,068.05 | 3,188,829,903.1 |
| 少数股东损益 | -7,128,381.11 | 17,656,860.73 | 2,972,421.98 | 1,132,947.86 |
| (一)基本每股收益 | 1.08 | 2.66 | 2.42 | 1.79 |
| (二)稀释每股收益 | 1.08 | 2.66 | 2.42 | 1.79 |
| 八、其他综合收益 | -122,538.7 | -13,441,329.34 | -5,079,332.38 | -8,020,440.18 |
| 归属于母公司股东的其他综合收益 | 28,469.89 | -11,725,184.18 | -4,915,956.31 | -8,367,865.6 |
| 九、综合收益总额 | 1,927,388,664.79 | 4,753,631,030.94 | 4,324,621,157.65 | 3,181,942,410.78 |
| 归属于母公司股东的综合收益总额 | 1,934,668,054.49 | 4,737,690,315.37 | 4,321,812,111.74 | 3,180,462,037.5 |
| 归属于少数股东的综合收益总额 | -7,279,389.7 | 15,940,715.57 | 2,809,045.91 | 1,480,373.28 |
| 公告日期 | 2025-04-29 | 2025-04-01 | 2024-10-30 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |